Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
申请人:JENAPHARM GmbH
公开号:EP0648778A2
公开(公告)日:1995-04-19
Beschrieben sind neue 11-Benzaldoximestradien-Derivate der allgemeinen Formel I
und deren pharmazeutisch annehmbare Salze, ein Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel.
Die beschriebenen Verbindungen zeigen starke antigestagene Wirkungen bei geringerer glucocorticoider Aktivität.
通式 I 的新型 11-苯甲醛肟雌二烯衍生物及其药学上可接受的盐类、其制备方法以及含有这些化合物的药物。
及其药学上可接受的盐、制备方法和含有这些化合物的药物。
所述化合物具有较低的糖皮质激素活性,同时具有较强的抗妊娠反应作用。
Neue 11-Benzaldoxim-17beta methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
申请人:JENAPHARM GmbH
公开号:EP0648779B1
公开(公告)日:1997-03-05
USE OF NITRIC OXIDE DONORS OR NITRIC OXIDE INHIBITORS FOR REGULATING CERVICAL DILATATION AND EXTENSIBILITY
申请人:Board of Regents, The University of Texas System
公开号:EP0814785B1
公开(公告)日:2007-11-07
GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
申请人:Bauzon Maxine
公开号:US20070179113A1
公开(公告)日:2007-08-02
The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
Interferon-beta gene therapy using an improved, regulated expression system
申请人:Bauzon Maxine
公开号:US20080076729A1
公开(公告)日:2008-03-27
The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.